Moran Wealth Management LLC Acquires Shares of 34,368 Prestige Consumer Healthcare Inc. $PBH

Moran Wealth Management LLC acquired a new stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) in the 1st quarter, HoldingsChannel.com reports. The institutional investor acquired 34,368 shares of the company’s stock, valued at approximately $2,037,000.

A number of other institutional investors also recently modified their holdings of the company. UMB Bank n.a. grew its position in Prestige Consumer Healthcare by 110.1% in the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after purchasing an additional 219 shares during the period. Bayforest Capital Ltd acquired a new position in Prestige Consumer Healthcare during the fourth quarter worth $29,000. Barrow Hanley Mewhinney & Strauss LLC lifted its stake in shares of Prestige Consumer Healthcare by 106.8% in the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock valued at $34,000 after buying an additional 283 shares in the last quarter. Torren Management LLC bought a new position in shares of Prestige Consumer Healthcare in the fourth quarter valued at $35,000. Finally, Caitong International Asset Management Co. Ltd grew its holdings in shares of Prestige Consumer Healthcare by 69.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock valued at $35,000 after buying an additional 236 shares during the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of the stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the sale, the vice president owned 42,820 shares in the company, valued at approximately $2,354,671.80. This trade represents a 2.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.50% of the company’s stock.

Prestige Consumer Healthcare Price Performance

PBH opened at $49.38 on Monday. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.57 and a quick ratio of 2.25. The company has a market capitalization of $2.34 billion, a price-to-earnings ratio of 12.63, a P/E/G ratio of 1.59 and a beta of 0.35. The firm’s fifty day moving average price is $49.36 and its two-hundred day moving average price is $58.25. Prestige Consumer Healthcare Inc. has a 1 year low of $42.62 and a 1 year high of $80.69.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Wednesday, May 13th. The company reported $1.23 EPS for the quarter, missing the consensus estimate of $1.39 by ($0.16). Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The firm had revenue of $281.62 million during the quarter, compared to analysts’ expectations of $293.64 million. During the same quarter in the prior year, the company earned $1.32 EPS. The business’s revenue for the quarter was down 5.0% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. As a group, analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PBH has been the subject of several recent research reports. Canaccord Genuity Group decreased their target price on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a research report on Friday, May 15th. Weiss Ratings cut shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, June 25th. Oppenheimer downgraded Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Finally, Zacks Research lowered Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a report on Monday, May 18th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of “Hold” and an average price target of $70.75.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).